Swanbridge Capital logo

Swanbridge Capital

Europe, Zuid-Holland, The Netherlands, Rotterdam

Description

Swanbridge Capital is a Rotterdam based venture capital fund.

Investor Profile

Swanbridge Capital has made 3 investments, with 2 in the past 12 months and 0% as lead.

Stage Focus

  • Seed (67%)
  • Series A (33%)

Country Focus

  • The Netherlands (100%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Life Science
  • Health Care
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Swanbridge Capital frequently co-invest with?

Thuja Capital
Europe, Utrecht, The Netherlands, Utrecht
Co-Investments: 1
Curie Capital
North America, Missouri, United States, Netherlands
Co-Investments: 1
Johnson & Johnson Innovation – JJDC
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
InnovationQuarter
Europe, Zuid-Holland, The Netherlands, The Hague
Co-Investments: 1
Co-Investments: 1
Qbic Fund
North America, Wisconsin, United States, Belgium
Co-Investments: 1
BOM
Europe, Noord-Brabant, The Netherlands, Tilburg
Co-Investments: 1
Erasmus MC
Europe, Zuid-Holland, The Netherlands, Rotterdam
Co-Investments: 1
Co-Investments: 1
Van Herk Ventures
Europe, Zuid-Holland, The Netherlands, Rotterdam
Co-Investments: 1

What are some of recent deals done by Swanbridge Capital?

Pan Cancer

Rotterdam, Zuid-Holland, The Netherlands

Pan Cancer exploits 20 years of pioneering research in the field of adoptive T-cell therapies.

BiotechnologyLife ScienceTherapeutics
SeedJul 11, 2024
Amount Raised: $4,608,685
Flindr Therapeutics

Amsterdam, Noord-Holland, The Netherlands

Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.

BiotechnologyHealth CareTherapeutics
Series AApr 24, 2024
Amount Raised: $21,400,056
Allero Therapeutics

Rotterdam, Zuid-Holland, The Netherlands

Allero Therapeutics is a biopharmaceutical company.

BiotechnologyPharmaceutical
SeedApr 17, 2019